The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

Anastasia Lanzi; F. A. Sinicrope; A. B. Benson; Jérôme Galon

doi:10.1080/2162402X.2020.1796003

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

Anastasia Lanzi, F. A. Sinicrope, A. B. Benson, Jérôme Galon

Gastroenterology and Hepatology

Research output: Contribution to journal › Review article › peer-review

Abstract

The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.

Original language	English (US)
Article number	1796003
Journal	OncoImmunology
Volume	9
Issue number	1
DOIs	https://doi.org/10.1080/2162402X.2020.1796003
State	Published - Jan 1 2020

Keywords

Immunoscore
cancer classification
immunity
phase 3 trial
prognosis
tumor microenvironment

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Oncology

Access to Document

10.1080/2162402X.2020.1796003

Cite this

@article{6b776b8396e64f9393e4984380062fe7,

title = "The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions",

abstract = "The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.",

keywords = "Immunoscore, cancer classification, immunity, phase 3 trial, prognosis, tumor microenvironment",

author = "Anastasia Lanzi and Sinicrope, {F. A.} and Benson, {A. B.} and J{\'e}r{\^o}me Galon",

note = "Publisher Copyright: {\textcopyright} 2020, {\textcopyright} 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.",

year = "2020",

month = jan,

day = "1",

doi = "10.1080/2162402X.2020.1796003",

language = "English (US)",

volume = "9",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "1",

}

TY - JOUR

T1 - The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

AU - Lanzi, Anastasia

AU - Sinicrope, F. A.

AU - Benson, A. B.

AU - Galon, Jérôme

PY - 2020/1/1

Y1 - 2020/1/1

N2 - The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.

AB - The consensus Immunoscore is a routine assay quantifying the adaptive immune response within the tumor microenvironment. It has a prognostic value that has been confirmed in a phase 3 clinical trial (NCCTG N0147) in stage III colon cancers. Moreover, results from another phase 3 randomized trial revealed the predictive value of Immunoscore for response to adjuvant chemotherapy duration. These results highlight the clinical utility of Immunoscore. In its latest edition, the World Health Organization classification of Digestive System Tumors introduced for the first time the immune response as an essential and desirable diagnostic criterion for colorectal cancer. Within the tumor microenvironment, the immune response provides an important estimate of the risk of recurrence and death in colon cancer. The international validation of the prognostic value of the consensus Immunoscore together with its prognostic value in the N0147 trial and its predictive utility for response to chemotherapy in stage III patients provide valuable information for patient management.

KW - Immunoscore

KW - cancer classification

KW - immunity

KW - phase 3 trial

KW - prognosis

KW - tumor microenvironment

UR - http://www.scopus.com/inward/record.url?scp=85088277374&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85088277374&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2020.1796003

DO - 10.1080/2162402X.2020.1796003

M3 - Review article

C2 - 32934890

AN - SCOPUS:85088277374

SN - 2162-4011

VL - 9

JO - OncoImmunology

JF - OncoImmunology

IS - 1

M1 - 1796003

ER -

The consensus Immunoscore in phase 3 clinical trial (N0147) and impact on patient management decisions

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this